Compare Moderna, Inc. (MRNA) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs VanEck Vietnam ETF — how do they compare? Moderna, Inc. trades at $220.84 (market cap $78.65B), while VanEck Vietnam ETF trades at $16.74 (market cap $469.76M). The key difference: Moderna, Inc. is far larger — about 167.4× VanEck Vietnam ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and VanEck Vietnam ETF for 51 Days on average.
| MRNA | VNM | |
|---|---|---|
Market Cap | $78.65B | $469.76M |
Volume | 37,373,437 | 375,157 |
Sector | Health | Sector/Thematic |
52-Week High | $203.46 | $19.80 |
52-Week Low | $22.36 | $16.34 |
Typical Hold Time | 59 Days | 51 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
VNM trades at $16.87, down 0.35% today, with a bearish technical signal from moving averages. The ETF faces sector concentration risks in real estate and financials while offering exposure to Vietnam's long-term growth potential. Recent news indicates Vietnam is nearing a trade deal with the US, which could provide macroeconomic support.
The outlook remains cautious due to technical weakness and sector headwinds, though selective capital rotation away from AI-heavy markets may benefit Vietnam-focused assets. Key risks include interest rate volatility and concentrated sector exposure limiting near-term upside despite fair valuations around 15x P/E.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
